<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="16975"><DrugName>methanesulfonyl fluoride (oral, Alzheimer's disease/cognitive disorder), SeneXta</DrugName><DrugSynonyms><Name><Value>Methylsulfonyl fluoride</Value></Name><Name><Value>MSF</Value></Name><Name><Value>MSF, Texas</Value></Name><Name><Value>methanesulfonyl fluoride, Texas</Value></Name><Name><Value>SNX-001</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>methanesulfonyl fluoride (oral, Alzheimer's disease/cognitive disorder), SeneXta</Value></Name><Name><Value>558-25-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1048093">University of Texas at El Paso</CompanyOriginator><CompaniesSecondary><Company id="1047827">SeneXta Therapeutics SA</Company><Company id="1048093">University of Texas at El Paso</Company><Company id="25566">Layton Bioscience Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="16975" type="Drug"><TargetEntity id="665810" type="siDrug"></TargetEntity><TargetEntity id="276280" type="siDrug">Methanesulfonyl fluoride</TargetEntity></SourceEntity><SourceEntity id="1047827" type="Company"><TargetEntity id="5035555192" type="organizationId">Senexta Therapeutics SA</TargetEntity></SourceEntity><SourceEntity id="1048093" type="Company"><TargetEntity id="4298218012" type="organizationId">University of Texas at El Paso</TargetEntity></SourceEntity><SourceEntity id="25566" type="Company"><TargetEntity id="5001139085" type="organizationId">Layton Bioscience Inc</TargetEntity></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"></TargetEntity><TargetEntity id="331.0" type="ICD9"></TargetEntity><TargetEntity id="10012271" type="MEDDRA"></TargetEntity><TargetEntity id="D000544" type="MeSH"></TargetEntity><TargetEntity id="-1268969445" type="omicsDisease"></TargetEntity><TargetEntity id="101" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="353" type="ciIndication"><TargetEntity id="10057668" type="MEDDRA"></TargetEntity><TargetEntity id="D019965" type="MeSH"></TargetEntity><TargetEntity id="-1363718134" type="omicsDisease"></TargetEntity><TargetEntity id="98" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="19" type="Action"><TargetEntity id="382" type="Mechanism">Acetylcholinesterase (AChE) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00043" type="ciTarget"><TargetEntity id="1580881301433" type="siTarget">Acetylcholinesterase</TargetEntity><TargetEntity id="8033" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="14">Alzheimers disease</Indication><Indication id="353">Cognitive disorder</Indication></IndicationsSecondary><ActionsPrimary><Action id="19">Acetylcholinesterase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="284">Nootropic agent</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>N7D1</Code><Name>Anti-Alzheimer products, cholinesterase inhibitors</Name></Ephmra><Ephmra><Code>N6D</Code><Name>NOOTROPICS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-01-19T06:01:52.000Z</LastModificationDate><ChangeDateLast>2019-01-21T00:00:00.000Z</ChangeDateLast><AddedDate>1998-01-20T16:35:55.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1047827" linkType="Company"&gt;SeneXta&lt;/ulink&gt;, under license from the &lt;ulink linkID="1048093" linkType="Company"&gt;University of Texas at El Paso&lt;/ulink&gt;, was developing  methanesulfonyl fluoride (MSF; SNX-001), an   acetylcholinesterase (AChE) inhibitor, for the potential oral treatment of Alzheimer's disease (AD) and post stroke cognitive impairment   [&lt;ulink linkID="1020006" linkType="Reference"&gt;1020006&lt;/ulink&gt;], [&lt;ulink linkID="1025320" linkType="Reference"&gt;1025320&lt;/ulink&gt;], [&lt;ulink linkID="1119719" linkType="Reference"&gt;1119719&lt;/ulink&gt;], [&lt;ulink linkID="1119718" linkType="Reference"&gt;1119718&lt;/ulink&gt;].   By July 2009, a phase I trial for AD had been initiated [&lt;ulink linkID="1025320" linkType="Reference"&gt;1025320&lt;/ulink&gt;]; in July 2010, the trial was completed   [&lt;ulink linkID="1119725" linkType="Reference"&gt;1119725&lt;/ulink&gt;]. In June 2012, the program was still listed as being in phase I development for AD [&lt;ulink linkID="1303382" linkType="Reference"&gt;1303382&lt;/ulink&gt;]. In July 2010, phase I trials were ongoing for post stroke cognitive impairment [&lt;ulink linkID="1119719" linkType="Reference"&gt;1119719&lt;/ulink&gt;]; in June 2012, development appeared to be ongoing [&lt;ulink linkID="1303382" linkType="Reference"&gt;1303382&lt;/ulink&gt;]. In December 2013, development was suspended due to financial constrain [&lt;ulink linkID="1511524" linkType="Reference"&gt;1511524&lt;/ulink&gt;], and development was presumably discontinued.&lt;/para&gt;&lt;para&gt;SeneXta is also investigating a second formulation of MSF, for an undisclosed indication. By July 2009, IND enabling studies were underway [&lt;ulink linkID="1020006" linkType="Reference"&gt;1020006&lt;/ulink&gt;], [&lt;ulink linkID="1025320" linkType="Reference"&gt;1025320&lt;/ulink&gt;]; in June 2012, this was still the case  [&lt;ulink linkID="1303382" linkType="Reference"&gt;1303382&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The compound was previously under development by the University of Texas at El Paso. By January 1998, phase II trials had begun [&lt;ulink linkID="275167" linkType="Reference"&gt;275167&lt;/ulink&gt;]. By October 2000, the University had licensed MSF to&lt;ulink linkID="25566" linkType="Company"&gt; Layton Bioscience&lt;/ulink&gt; [&lt;ulink linkID="294868" linkType="Reference"&gt;294868&lt;/ulink&gt;]. However, by September 2006, Layton Bioscience had ceased trading and all rights reverted back to the University of Texas at El Paso [&lt;ulink linkID="942278" linkType="Reference"&gt;942278&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By July 2009, the company planned to initiate  phase II AD trials  in 2010 [&lt;ulink linkID="1025320" linkType="Reference"&gt;1025320&lt;/ulink&gt;]. In July 2010, the company planned to initiate the randomized, multi-center, placebo-controlled  trial in  300 patients for 6 months  plus 6 months follow-up in the first quarter of 2011 [&lt;ulink linkID="1119719" linkType="Reference"&gt;1119719&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2009, an IND and an IMPD had been filed and a phase I trial  had begun [&lt;ulink linkID="1025320" linkType="Reference"&gt;1025320&lt;/ulink&gt;]. In July 2010, a randomized, double-blind, placebo-controlled, single and multiple dose-escalation, phase I trial in 24-subjects was completed. Subjects received one of three different doses of the drug or placebo showed AChE inhibition in RBC, dose-proportional pharmacokinetics and low inter-subject variability. The drug was safe and well tolerated [&lt;ulink linkID="1119725" linkType="Reference"&gt;1119725&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2009,  a proof-of-concept, double blind, placebo-controlled, cross over study of SNX-001 demonstrated a clinically significant mean of six point improvement on the Alzheimer's Disease Assessment Scale-cognitive subscale (ADASCog)  [&lt;ulink linkID="1025320" linkType="Reference"&gt;1025320&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The earliest clinical results demonstrated the potential efficacy of MSF in the treatment of senile dementia of the Alzheimer's type (SDAT). Experiment I, in which MSF was administered orally (0.03 to 0.18 mg/kg) to ten volunteers, showed that it produced a mean of 89.5% inhibition of erythrocyte AChE function. Experiment II was a 16-week, double-blind, cross-over study. A total of 15 aged people with SDAT were administered MSF at doses up to 0.18 mg/kg three times a week. Compared to placebo, MSF treatment improved cognitive performance, as measured by various scales such as MMSE (2.7), ADAS-COG (c.5), GDS (4.4 to 3.1) and CIBIC (1). No patients left the study due to adverse effects and there were no toxic effects [&lt;ulink linkID="293518" linkType="reference"&gt;293518&lt;/ulink&gt;], [&lt;ulink linkID="372928" linkType="reference"&gt;372928&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By July 2010, ex vivo studies conducted in mice, rats, and monkey cortex demonstrated that the drug had shown 80% inhibition of AChE with out toxicity. In vitro studies demonstrated that the drug had shown AChE inhibition in human cortex compared to butyrylcholinesterase. In vivo studies demonstrated that the drug had shown efficacy of reversing scopolamine-induced amnesia, normal age-related memory impairment and ischemia-induced cognitive deficits in rats. Dose response study was conducted in monkeys. Monkeys were administered with therapeutic dose on every other day about 5 weeks had shown 80% AChE inhibition. By that time, all GLP toxicology and safety pharmacological studies including LD50, pharmacokinetic, ADME, 28-day toxicological (rat and dog), genotoxicity, hERG, CNS-pharmacological and respiratory had been completed [&lt;ulink linkID="1119720" linkType="Reference"&gt;1119720&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2009, the company planned to initiate  IND-enabling studies for post stroke cognitive impairement in the first quarter of 2010  [&lt;ulink linkID="1025320" linkType="Reference"&gt;1025320&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2009, toxicology studies were completed for AD [&lt;ulink linkID="1025320" linkType="Reference"&gt;1025320&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2008, SeneXta had begun preclinical studies of MSF [&lt;ulink linkID="1019938" linkType="Reference"&gt;1019938&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;By July 2009, SeneXta was developing a new delivery technology  [&lt;ulink linkID="1025320" linkType="Reference"&gt;1025320&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2009, SeneXta signed an agreement with University of Texas at El Paso  for the development and marketing of MSF [&lt;ulink linkID="1025352" linkType="Reference"&gt;1025352&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1047827">SeneXta Therapeutics SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="353">Cognitive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-12-26T00:00:00.000Z</StatusDate><Source id="1511524" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25566">Layton Bioscience Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-09-25T00:00:00.000Z</StatusDate><Source id="942278" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1047827">SeneXta Therapeutics SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-12-26T00:00:00.000Z</StatusDate><Source id="1511524" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1048093">University of Texas at El Paso</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-01-27T00:00:00.000Z</StatusDate><Source id="1025352" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1047827">SeneXta Therapeutics SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-07-13T00:00:00.000Z</StatusDate><Source id="1025320" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1047827">SeneXta Therapeutics SA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="353">Cognitive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-07-28T00:00:00.000Z</StatusDate><Source id="1119719" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1048093">University of Texas at El Paso</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><Source id="275167" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1048093">University of Texas at El Paso</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><Source id="275167" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1047827">SeneXta Therapeutics SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-12-26T00:00:00.000Z</StatusDate><Source id="1511524" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1047827">SeneXta Therapeutics SA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="353">Cognitive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-12-26T00:00:00.000Z</StatusDate><Source id="1511524" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25566">Layton Bioscience Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-10-11T00:00:00.000Z</StatusDate><Source id="294868" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1048093">University of Texas at El Paso</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-01-20T00:00:00.000Z</StatusDate><Source id="275167" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1047827">SeneXta Therapeutics SA</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="353">Cognitive disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-11-30T00:00:00.000Z</StatusDate><Source id="1019938" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00043"><Name>Acetylcholinesterase</Name><SwissprotNumbers><Swissprot>Q86GC8</Swissprot><Swissprot>Q86GC9</Swissprot><Swissprot>Q92035</Swissprot><Swissprot>Q92081</Swissprot><Swissprot>Q9DDE3</Swissprot><Swissprot>O42275</Swissprot><Swissprot>O62763</Swissprot><Swissprot>P04058</Swissprot><Swissprot>P07140</Swissprot><Swissprot>P07692</Swissprot><Swissprot>P21836</Swissprot><Swissprot>P22303</Swissprot><Swissprot>P23795</Swissprot><Swissprot>P36196</Swissprot><Swissprot>P37136</Swissprot><Swissprot>P56161</Swissprot><Swissprot>Q27677</Swissprot><Swissprot>Q29499</Swissprot><Swissprot>Q867X2</Swissprot><Swissprot>Q867X3</Swissprot><Swissprot>Q869C3</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1047827">SeneXta Therapeutics SA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="1067798">Transparency Life Sciences LLC</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21864">University of Texas System</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="25566">Layton Bioscience Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>1</CountInactive><CountTotal>3</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CS(=O)(=O)F</Smiles></StructureSmiles><Deals><Deal id="117509" title="Layton Bioscience to develop the University of Texas' methanesofonyl fluoride"></Deal><Deal id="128709" title="SeneXta to develop and market University of Texas's MSF in worldwide "></Deal><Deal id="157713" title="TLC to acquire an option to develop and commercialize SeneXta's acetylcholinesterase against CNS disease       "></Deal></Deals><PatentFamilies><PatentFamily id="1649921" number="WO-09808497" title="Sulfonyl fluorides for the treatment of Alzheimer{&amp;amp;lsquo}s disease."></PatentFamily><PatentFamily id="518439" number="US-20080213410" title="Anti-human papillomas virus topical composition"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Texas System" id="21864"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Layton Bioscience Inc" id="25566"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>